Literature DB >> 25817897

Recurrent intestinal metaplasia after radiofrequency ablation for Barrett's esophagus: endoscopic findings and anatomic location.

Cary C Cotton1, W Asher Wolf1, Sarina Pasricha1, Nan Li1, Ryan D Madanick1, Melissa B Spacek1, Kathleen Ferrell1, Evan S Dellon1, Nicholas J Shaheen1.   

Abstract

BACKGROUND: Radiofrequency ablation (RFA) is a safe and effective treatment for Barrett's esophagus (BE) that results in high rates of complete eradication of intestinal metaplasia (CEIM). However, recurrence is common after CEIM, and surveillance endoscopy is recommended. Neither the anatomic location nor the endoscopic appearance of these recurrences is well-described.
OBJECTIVE: Describe the location of histologic specimens positive for recurrence after CEIM and the testing performance of endoscopic findings for the histopathologic detection of recurrence.
DESIGN: Retrospective cohort.
SETTING: Single referral center. PATIENTS: A total of 198 patients with BE with at least 2 surveillance endoscopies after CEIM.
INTERVENTIONS: RFA, EMR, surveillance endoscopy. MAIN OUTCOME MEASUREMENTS: The anatomic location and histologic grade of recurrence.
RESULTS: In a mean 3.0 years of follow-up, 32 (16.2%; 95% confidence interval [CI], 11.0%-22.0%) patients had recurrence of disease, 5 (2.5%; 95% CI, 0.3%-4.7%) of whom progressed beyond their worst before-treatment histology. Recurrence was most common at or near the gastroesophageal junction (GEJ). Recurrence>1 cm proximal to the GEJ always was accompanied by endoscopic findings, and random biopsies in these areas detected no additional cases. The sensitivity of any esophageal sign under high-definition white light or narrow-band imaging for recurrence was 59.4% (42.4%, 76.4%), and the specificity was 80.6% (77.2%, 84.0%). LIMITATIONS: Single-center study.
CONCLUSION: Recurrent intestinal metaplasia often is not visible to the endoscopist and is most common near the GEJ. Random biopsies>1 cm above the GEJ had no yield for recurrence. In addition to biopsy of prior EMR sites and of suspicious lesions, random biopsies oversampling the GEJ are recommended.
Copyright © 2015 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25817897      PMCID: PMC4439393          DOI: 10.1016/j.gie.2014.12.029

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  23 in total

Review 1.  Buried metaplasia after endoscopic ablation of Barrett's esophagus: a systematic review.

Authors:  Nathan A Gray; Robert D Odze; Stuart Jon Spechler
Journal:  Am J Gastroenterol       Date:  2011-08-09       Impact factor: 10.864

2.  Biopsy depth after radiofrequency ablation of dysplastic Barrett's esophagus.

Authors:  Nicholas J Shaheen; Anne F Peery; Bergein F Overholt; Charles J Lightdale; Amitabh Chak; Kenneth K Wang; Robert H Hawes; David E Fleischer; John R Goldblum
Journal:  Gastrointest Endosc       Date:  2010-07-03       Impact factor: 9.427

3.  Validation of the Prague C & M criteria for the endoscopic grading of Barrett's esophagus by gastroenterology trainees: a multicenter study.

Authors:  Babac Vahabzadeh; Anil B Seetharam; Michael B Cook; Sachin Wani; Amit Rastogi; Ajay Bansal; Dayna S Early; Prateek Sharma
Journal:  Gastrointest Endosc       Date:  2012-02       Impact factor: 9.427

Review 4.  Barrett oesophagus in 2013: risk stratification and surveillance in Barrett oesophagus.

Authors:  Emmanuel C Gorospe; Kenneth K Wang
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-12-10       Impact factor: 46.802

5.  A survey of expert follow-up practices after successful endoscopic eradication therapy for Barrett's esophagus with high-grade dysplasia and intramucosal adenocarcinoma.

Authors:  Aarti O Bedi; Richard S Kwon; Joel H Rubenstein; Cyrus R Piraka; Grace H Elta; James M Scheiman; B Joseph Elmunzer
Journal:  Gastrointest Endosc       Date:  2013-05-24       Impact factor: 9.427

Review 6.  A cost-utility analysis of ablative therapy for Barrett's esophagus.

Authors:  John M Inadomi; Ma Somsouk; Ryan D Madanick; Jennifer P Thomas; Nicholas J Shaheen
Journal:  Gastroenterology       Date:  2009-03-06       Impact factor: 22.682

7.  Radiofrequency ablation in Barrett's esophagus with dysplasia.

Authors:  Nicholas J Shaheen; Prateek Sharma; Bergein F Overholt; Herbert C Wolfsen; Richard E Sampliner; Kenneth K Wang; Joseph A Galanko; Mary P Bronner; John R Goldblum; Ana E Bennett; Blair A Jobe; Glenn M Eisen; M Brian Fennerty; John G Hunter; David E Fleischer; Virender K Sharma; Robert H Hawes; Brenda J Hoffman; Richard I Rothstein; Stuart R Gordon; Hiroshi Mashimo; Kenneth J Chang; V Raman Muthusamy; Steven A Edmundowicz; Stuart J Spechler; Ali A Siddiqui; Rhonda F Souza; Anthony Infantolino; Gary W Falk; Michael B Kimmey; Ryan D Madanick; Amitabh Chak; Charles J Lightdale
Journal:  N Engl J Med       Date:  2009-05-28       Impact factor: 91.245

8.  Volumetric laser endomicroscopy detects subsquamous Barrett's adenocarcinoma.

Authors:  Cadman L Leggett; Emmanuel Gorospe; Victoria L Owens; Marlys Anderson; Lori Lutzke; Kenneth K Wang
Journal:  Am J Gastroenterol       Date:  2014-02       Impact factor: 10.864

9.  Systematic four-quadrant biopsy detects Barrett's dysplasia in more patients than nonsystematic biopsy.

Authors:  Jo-Etienne Abela; James J Going; John F Mackenzie; Margaret McKernan; Sylvia O'Mahoney; Robert C Stuart
Journal:  Am J Gastroenterol       Date:  2008-03-26       Impact factor: 10.864

10.  Narrow band imaging does not reliably predict residual intestinal metaplasia after radiofrequency ablation at the neo-squamo columnar junction.

Authors:  Lorenza Alvarez Herrero; Wouter L Curvers; Raf Bisschops; Mohammed A Kara; Erik J Schoon; Fiebo J W ten Kate; Mike Visser; Bas L A M Weusten; Jacques J G H M Bergman
Journal:  Endoscopy       Date:  2014-01-29       Impact factor: 10.093

View more
  15 in total

1.  Development of Evidence-Based Surveillance Intervals After Radiofrequency Ablation of Barrett's Esophagus.

Authors:  Cary C Cotton; Rehan Haidry; Aaron P Thrift; Laurence Lovat; Nicholas J Shaheen
Journal:  Gastroenterology       Date:  2018-04-13       Impact factor: 22.682

Review 2.  Barrett's esophagus: diagnosis and management.

Authors:  Swathi Eluri; Nicholas J Shaheen
Journal:  Gastrointest Endosc       Date:  2017-01-18       Impact factor: 9.427

3.  Recurrence of Barrett's Esophagus is Rare Following Endoscopic Eradication Therapy Coupled With Effective Reflux Control.

Authors:  Srinadh Komanduri; Peter J Kahrilas; Kumar Krishnan; Tim McGorisk; Kiran Bidari; David Grande; Laurie Keefer; John Pandolfino
Journal:  Am J Gastroenterol       Date:  2017-02-14       Impact factor: 10.864

Review 4.  Development of Quality Indicators for Endoscopic Eradication Therapies in Barrett's Esophagus: The TREAT-BE (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus) Consortium.

Authors:  Sachin Wani; V Raman Muthusamy; Nicholas J Shaheen; Rena Yadlapati; Robert Wilson; Julian A Abrams; Jacques Bergman; Amitabh Chak; Kenneth Chang; Ananya Das; John Dumot; Steven A Edmundowicz; Glenn Eisen; Gary W Falk; M Brian Fennerty; Lauren Gerson; Gregory G Ginsberg; David Grande; Matt Hall; Ben Harnke; John Inadomi; Janusz Jankowski; Charles J Lightdale; Jitin Makker; Robert D Odze; Oliver Pech; Richard E Sampliner; Stuart Spechler; George Triadafilopoulos; Michael B Wallace; Kenneth Wang; Irving Waxman; Srinadh Komanduri
Journal:  Am J Gastroenterol       Date:  2017-06-01       Impact factor: 10.864

Review 5.  Quality Indicators in Endoscopic Ablation for Barrett's Esophagus.

Authors:  Samuel Han; Sachin Wani
Journal:  Curr Treat Options Gastroenterol       Date:  2017-06

6.  Acidic Bile Salts Induce Epithelial to Mesenchymal Transition via VEGF Signaling in Non-Neoplastic Barrett's Cells.

Authors:  Qiuyang Zhang; Agoston T Agoston; Thai H Pham; Wei Zhang; Xi Zhang; Xiaofang Huo; Sui Peng; Manisha Bajpai; Kiron Das; Robert D Odze; Stuart J Spechler; Rhonda F Souza
Journal:  Gastroenterology       Date:  2018-09-27       Impact factor: 22.682

Review 7.  Chemoprevention of Barrett's Esophagus and Esophageal Adenocarcinoma.

Authors:  Robert S Bresalier
Journal:  Dig Dis Sci       Date:  2018-08       Impact factor: 3.199

Review 8.  Risk of recurrence of Barrett's esophagus after successful endoscopic therapy.

Authors:  Rajesh Krishnamoorthi; Siddharth Singh; Karthik Ragunathan; David A Katzka; Kenneth K Wang; Prasad G Iyer
Journal:  Gastrointest Endosc       Date:  2016-02-20       Impact factor: 9.427

9.  Cryotherapy and Radiofrequency Ablation for Eradication of Barrett's Esophagus with Dysplasia or Intramucosal Cancer.

Authors:  Prashanthi N Thota; Zubin Arora; John A Dumot; Gary Falk; Tanmayee Benjamin; John Goldblum; Sunguk Jang; Rocio Lopez; John J Vargo
Journal:  Dig Dis Sci       Date:  2018-03-09       Impact factor: 3.199

Review 10.  Natural History of the Post-ablation Esophagus.

Authors:  Craig C Reed; Nicholas J Shaheen
Journal:  Dig Dis Sci       Date:  2018-08       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.